三阴乳腺癌临床病理特征与分子标志物的相关性  

Correlation between clinicopathological features of triplenegative breast cancer and molecular markers

作　　者：王晶晶[1,2] 张旭辉[2] 冯晓燕[2] 房涛[2] WANG Jingjing ZHANG Xuhui FENG Xiaoyan FANG Tao(Department of Pathology, The Affiliated Hospital of Military Medical Sciences, Beijing 100071 Department of Bio-diagnosis, Institute of Basic Medical Sciences, Academy of Military Medical Sciences, Beijing 100850, China)

机构地区：[1]军事医学科学院附属医院病理科,北京100071 [2]军事医学科学院基础医学研究所,北京100850

出　　处：《临床与病理杂志》2017年第2期408-411,共4页Journal of Clinical and Pathological Research

基　　金：国家自然科学基金(81672607);国家重点研发计划(2016YFC0106603)~~

摘　　要：三阴乳腺癌(triple-negative breast cancer,TNBC)即雌激素受体(estrogen receptor,ER)、孕激素受体(progestogen receptor,PR)、人表皮生长因子受体-2(human epithelial growth factor receptor-2,H E R-2)均为阴性的乳腺癌。对内分泌治疗和抗HER-2的治疗无效,其分子亚型较多,存在基因表达差异,异质性明显,缺乏有效的分子靶标,且具有较高的侵袭转移率及复发率、预后差,临床病理学特征独特,因此探寻TNBC的临床病理特征及其分子标志物,对临床进一步诊断及治疗TNBC具有重要意义。Triple-negative breast cancer （TNBC） is characterized by a lack of estrogen receptor （ER）, progesterone receptor （PR） and human epidermal growth factor receptor-2 （HER-2） expressions. TNBC is invalid for endocrine therapy and anti-HER-2 therapy. TNBC is a heterogeneous breast cancer group and lacks of effective molecular targets. As its unique clinical pathological features with high rate of invasion and metastasis, recurrence, and unfavorable prognosis, exploring the clinicopathological features and molecular markers is necessary for clinical diagnosis and treatment of TNBC patients.

关 键 词：三阴乳腺癌 临床病理特征 分子标志物 

分 类 号：R737.9[医药卫生—肿瘤]